EPCAM and prostate cancer: A series of platforms have been launched for CTC detection in clinical and research settings: CellSearch, the first and the only Food and Drug Administration (FDA) approved CTC test, detect CTCs in patients with breast, colorectal, and prostate cancer (EpCAM+, cytokeratin 8+, 18+ and/or 19+ and CD45−); Epic Sciences capture CTCs and classify them based on molecular markers (EpCAM, cytokeratins, HER2, androgen receptors, etc.)and morphological features including size and shape.